Fly News Breaks for March 5, 2019
Mar 5, 2019 | 07:28 EDT
As previously reported, Morgan Stanley analyst David Lebowitz upgraded Alnylam to Overweight from Equal Weight, stating that he expects Onpattro to ultimately exceed the Street's expectations for 2019 given early metrics about the drug's launch. Even modest sequential adds as the year progresses to the 200 patients on the drug at year-end 2018 should put it on track to beat his 2019 sales estimate of $105M, as well as consensus of $94M, said Lebowitz. He also expects positive news flow from the company's late stage pipeline, particularly Givosiran and Lumasiran. Lebowitz raised his price target on Alnylam shares to $122 from $81.
News For ALNY From the Last 2 Days
There are no results for your query ALNY